Fabry disease
FDA approves first oral therapy for rare Fabry disease
August 13, 2018Sales and Marketing FDA, Fabry disease, US, pharma
Amicus has revealed that its therapy Galafold (migalastat) has been awarded approval by the FDA in the treatment of adult …
Amicus Therapeutics’ Fabry disease drug gets European regulatory support
April 4, 2016Research and Development, Sales and Marketing Amicus Therapeutics, EMA, Fabry disease, genetic disorder, rare disease
Shares in biotechnology firm Amicus Therapeutics (Nasdaq: FOLD) rose to close up nearly 3% after the European regulators announced backing …
Shire facility could answer rare disease drug shortage
November 27, 2011Manufacturing and Production Fabry disease, Gaucher, Shire, Vpriv
Shire has filed applications with the European and US regulators to produce its Gaucher disease drug Vpriv (velaglucerase alfa) at …
GSK-Amicus start late-stage trials of Fabry disease treatment
September 14, 2011Research and Development Amicus Therapeutics, Fabry disease, GSK
GlaxoSmithKline and Amicus Therapeutics are moving forward with their phase III programme for Fabry disease treatment Amigal. The first patient …
Shire sales rocket with 25% growth
July 29, 2011Sales and Marketing ADHD, Fabry disease, Gaucher's disease, Shire
Specialist pharma company Shire has posted exceptionally strong results for the second quarter, increasing its product sales by 30% and …
GSK signs rare diseases deal with Amicus
November 1, 2010Research and Development, Sales and Marketing Amicus Therapeutics, Fabrazyme, Fabry disease, GSK, GlaxoSmithKline, pharmacological chaperones
GlaxoSmithKline is partnering with US biopharmaceutical company Amicus Therapeutics to develop and commercialise its late-stage Fabry disease drug Amigal. GSK …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
